EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY-NC-ND 4.0

Evaluating artificial intelligence–enhanced digital urine cytology for bladder cancer diagnosis

Tien-Jen Liu, Wen-Chi Yang, Shin-Min Huang, Wei-Lei Yang, Hsing-Ju Wu, Hui Wen Ho, Shih-Wen Hsu, Cheng-Hung Yeh, Ming-Yu Lin, Yi-Ting Hwang, Pei-Yi Chu

Cancer Cytopathology · 2024-11 · 132 (11) · 686-695

DOI: 10.1002/cncy.22884 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Cancer Cytopathology, online erschienen am 14.07.2024. Verfasst von Tien-Jen Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: AIxMed, Inc., Santa Clara, California, USA. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Artificial Intelligence, Cytodiagnosis. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AIxMed, Inc, The National Science and Technology Council-Central Taiwan Science Park.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study evaluated the diagnostic effectiveness of the AIxURO platform, an artificial intelligence–based tool, to support urine cytology for bladder cancer management, which typically requires experienced cytopathologists and substantial diagnosis time.

Methods

One cytopathologist and two cytotechnologists reviewed 116 urine cytology slides and corresponding whole‐slide images (WSIs) from urology patients. They used three diagnostic modalities: microscopy, WSI review, and AIxURO, per The Paris System for Reporting Urinary Cytology (TPS) criteria. Performance metrics, including TPS‐guided and binary diagnosis, inter‐ and intraobserver agreement, and screening time, were compared across all methods and reviewers.

Results

AIxURO improved diagnostic accuracy by increasing sensitivity (from 25.0%–30.6% to 63.9%), positive predictive value (PPV; from 21.6%–24.3% to 31.1%), and negative predictive value (NPV; from 91.3%–91.6% to 95.3%) for atypical urothelial cell (AUC) cases. For suspicious for high‐grade urothelial carcinoma (SHGUC) cases, it improved sensitivity (from 15.2%–27.3% to 33.3%), PPV (from 31.3%–47.4% to 61.1%), and NPV (from 91.6%–92.7% to 93.3%). Binary diagnoses exhibited an improvement in sensitivity (from 77.8%–82.2% to 90.0%) and NPV (from 91.7%–93.4% to 95.8%). Interobserver agreement across all methods showed moderate consistency (κ = 0.57–0.61), with the cytopathologist demonstrating higher intraobserver agreement than the two cytotechnologists across the methods (κ = 0.75–0.88). AIxURO significantly reduced screening time by 52.3%–83.2% from microscopy and 43.6%–86.7% from WSI review across all reviewers. Screening‐positive (AUC+) cases required more time than negative cases across all methods and reviewers.

Conclusions

AIxURO demonstrates the potential to improve both sensitivity and efficiency in bladder cancer diagnostics via urine cytology. Its integration into the cytopathological screening workflow could markedly decrease screening times, which would improve overall diagnostic processes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsArtificial IntelligenceCytodiagnosisHumansUrineFemaleMaleCarcinoma, Transitional CellSensitivity and SpecificityMicroscopyAged

Stichwörter der Autor:innen

The Paris System for Reporting Urinary Cytologyartificial intelligencebladder cancerdigital cytopathologyurine cytologywhole‐slide image

Autor:innen und Institutionen

  • AIxMed, Inc., Santa Clara, California, USA.
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
  • Department of Pathology, Show Chwan Memorial Hospital, Changhua, Taiwan.
  • Research Assistant Center, Show Chwan Memorial Hospital, Changhua, Taiwan.
  • Department of Statistics, National Taipei University, Taipei, Taiwan.
  • School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.

Förderung

  • AIxMed, Inc
  • The National Science and Technology Council-Central Taiwan Science Park

Zitieren

APA

Liu, T. J., Yang, W. C., Huang, S. M., Yang, W. L., Wu, H. J., Ho, H. W., Hsu, S. W., Yeh, C. H., Lin, M. Y., Hwang, Y. T., & Chu, P. Y. (2024). Evaluating artificial intelligence–enhanced digital urine cytology for bladder cancer diagnosis. Cancer Cytopathology, 132(11), 686-695. https://doi.org/10.1002/cncy.22884

Vancouver

Liu TJ, Yang WC, Huang SM, Yang WL, Wu HJ, Ho HW, et al. Evaluating artificial intelligence–enhanced digital urine cytology for bladder cancer diagnosis. Cancer Cytopathology. 2024;132(11):686-695. doi:10.1002/cncy.22884

BibTeX
@article{Liu2024,
  author = {Liu, Tien-Jen and Yang, Wen-Chi and Huang, Shin-Min and Yang, Wei-Lei and Wu, Hsing-Ju and Ho, Hui Wen and Hsu, Shih-Wen and Yeh, Cheng-Hung and Lin, Ming-Yu and Hwang, Yi-Ting and Chu, Pei-Yi},
  title = {Evaluating artificial intelligence–enhanced digital urine cytology for bladder cancer diagnosis},
  journal = {Cancer Cytopathology},
  year = {2024},
  volume = {132},
  number = {11},
  pages = {686--695},
  doi = {10.1002/cncy.22884}
}
Kostenlos starten →